Results 161 to 170 of about 28,618 (205)
Special Issue "Purinergic Signalling in Physiology and Pathophysiology 2.0". [PDF]
Sluyter R.
europepmc +1 more source
CD39 Regulation and Functions in T Cells [PDF]
CD39 is an enzyme which is responsible, together with CD73, for a cascade converting adenosine triphosphate into adenosine diphosphate and cyclic adenosine monophosphate, ultimately leading to the release of an immunosuppressive form of adenosine in the tumor microenvironment.
Eleonora Timperi +2 more
exaly +3 more sources
CD39 and control of cellular immune responses [PDF]
CD39 is the cell surface-located prototypic member of the ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase) family. Biological actions of CD39 are a consequence (at least in part) of the regulated phosphohydrolytic activity on extracellular nucleotides.
Karen M Dwyer +2 more
exaly +7 more sources
Implications of CD39 in immune-related diseases
Extracellular adenosine triphosphate (eATP) mediates pro-inflammatory responses by recruiting and activating inflammatory cells. CD39 can hydrolyze eATP into adenosine monophosphate (AMP), while CD73 can convert AMP into the immunosuppressive nucleoside adenosine (ADO).
Zhaochen Ning +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Nature Reviews Immunology, 2020
The ATP-adenosine pathway functions as a key modulator of innate and adaptive immunity within the tumour microenvironment. Consequently, multiple clinical strategies are being explored to target this pathway for the treatment of cancer; in particular, recent clinical data with CD73 antagonists and inhibitors of A2A receptors have demonstrated the ...
Achim K. Moesta +2 more
openaire +5 more sources
The ATP-adenosine pathway functions as a key modulator of innate and adaptive immunity within the tumour microenvironment. Consequently, multiple clinical strategies are being explored to target this pathway for the treatment of cancer; in particular, recent clinical data with CD73 antagonists and inhibitors of A2A receptors have demonstrated the ...
Achim K. Moesta +2 more
openaire +5 more sources
CD39 as a Caveolar-Associated Ectonucleotidase
Biochemical and Biophysical Research Communications, 1999CD39 is a human lymphoid cell activation antigen, (also referred to E-ATPDase or apyrase) that hydrolyzes extracellular ATP and ADP. Although it has been widely studied, its physiological role, however, still remains unclear. This ectonucleotidase generally is said to be evenly distributed in the membrane of the cells. However, we observed that in cell
A, Kittel +5 more
openaire +2 more sources
Blood, 2013
In this issue of Blood , Hohmann et al describe a new antithrombotic strategy that involves delayed targeting of CD39 to activated platelets, which reduces thrombus size without increasing bleeding.[1][1] ![Figure][2] (A) Platelet thrombus formation occurs in a stepwise process.
openaire +2 more sources
In this issue of Blood , Hohmann et al describe a new antithrombotic strategy that involves delayed targeting of CD39 to activated platelets, which reduces thrombus size without increasing bleeding.[1][1] ![Figure][2] (A) Platelet thrombus formation occurs in a stepwise process.
openaire +2 more sources
Science Translational Medicine, 2012
Overexpression of CD39 in the lungs helps clear bacteria.
openaire +1 more source
Overexpression of CD39 in the lungs helps clear bacteria.
openaire +1 more source
Abstract B3: CD39+ cancer cells mediate immunosuppression reverted by CD39-blocking antibodies.
Cancer Research, 2013Abstract The CD39 and CD73 ectonucleotidases hydrolyze extracellular ATP and ADP into immunosuppressive adenosine that binds adenosine receptor and inhibits T cell and NK cell responses. It has been demonstrated that CD39+ Tregs are increased in some human cancers and participate to immunosuppression.
Anne Regairaz +6 more
openaire +1 more source

